Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis

Internal Medicine

Volumn 48, Issue 16, 2009, Pages 1363-1368

  Sari, Ismail ^a   Kebapcilar, Levent ^a   Alacacioglu, Ahmet ^a   Bilgi, Oktay ^a   Yildiz, Yasar ^a   Taylan, Ali ^b   Yukel, Arif ^a   Kozaci, Didem L ^c  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

^b Izmir Tepecik Training and Research Hospital   (Turkey)

^c ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Ankylosing spondylitis; Asymmetric dimethylarginine; Atherosclerosis; Endothelin 1; Endothelium

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; ETANERCEPT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ARGININE; BIOLOGICAL MARKERS; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RISK FACTORS; SPONDYLITIS, ANKYLOSING; UP-REGULATION;

EID: 70349546855     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2193     Document Type: Article

References (28)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 369: 1379-1390, 2007.
2. van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am 24: 663-676, 1998.
3. Okan T, Sari I, Akar S, et al. Ventricular diastolic function of ankylosing spondylitis patients by using conventional pulsed wave Doppler, myocardial performance index and tissue Doppler imaging. Echocardiography 25: 47-56, 2008.
4. Kaprove RE, Little AH, Graham DC, Rosen PS. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum 23: 57-61, 1980.
5. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52: 174-176, 1993.
6. Radford EP, Doll R, Smith PG. Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 297: 572-576, 1977.
7. Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with x rays. Br Med J (Clin Res Ed) 284: 449-460, 1982.
8. Khan MA, Khan MK, Kushner I. Survival among patients with ankylosing spondylitis: a life-table analysis. J Rheumatol 8: 86-90, 1981.
9. Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 45: 283-286, 2006.
10. Surdacki A, Martens-Lobenhoffer J, Wloch A, et al. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 56: 809-819, 2007.
11. Terekeci HM, Oktenli C, Ozgurtas T, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol 35: 2024-2029, 2008.
12. Sahin M, Arslan C, Naziroglu M, et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. Ann Clin Lab Sci 36: 449-454, 2006.
13. Pache M, Schwarz HA, Kaiser HJ, et al. Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit 8: CR616-CR619, 2002.
14. Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 54: 361-365, 1995.
15. Ural AU, Yalcin A, Beyan C, Isimer A, Bayhan H. Plasma endothelin-1 concentrations in patients with Behcet's disease. Scand J Rheumatol 23: 322-325, 1994.
16. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27: 361-368, 1984.
17. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21: 1694-1698, 1994.
18. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21: 2281-2285, 1994.
19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21: 2286-2291, 1994.
20. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38: 126-136, 2006.
21. Boger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 43: 1124-1129, 2005.
22. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128, 2001.
23. Bultink IE, Teerlink T, Heijst JA, Dijkmans BA, Voskuyl AE. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann Rheum Dis 64: 1362-1365, 2005.
24. Dooley A, Gao B, Bradley N, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 45: 676-684, 2006.
25. van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after TNF{alpha} blockade. Ann Rheum Dis 68: 362-366, 2009.
26. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86: 485-498, 2008.
27. Goraca A. New views on the role of endothelin (minireview). Endocr Regul 36: 161-167, 2002.
28. Morelli S, Ferri C, Di Francesco L, et al. Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension. Ann Rheum Dis 54: 730-734, 1995.